SALT LAKE CITY, March 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Noridian Administrative Services LLC ("Noridian"), Medicare administrative contractor for Jurisdiction F which includes Utah, has priced the new molecular pathology codes for calendar year 2013. Since all of Myriad's tests reimbursed by Medicare are performed in its Utah laboratory, these rates will be applicable for Myriad's Medicare reimbursement this year.
Noridian pricing for the new molecular pathology codes is as follows:
|Molecular Diagnostic Tests||CY13 Price||Reimbursement||Difference|
|• Integrated BRAC Analysis ®||$3,382||$3,680||(8.1%)|
|(Codes 81211, 81213)|
|• COLARIS ®||$4,343||$3,800||(14.3%)|
|(Codes 81292, 81294, 81295,|
|81297, 81298, 81300, 81317,|
Fiscal Year 2013 OutlookThe Company currently expects total revenues for FY 2013 to be at the high end of the $575 million to $585 million previous guidance range and diluted earnings per share to be at the high end of the $1.55 to $1.58 previous guidance range. These projections are forward looking statements and are subject to the risks summarized in the Safe Harbor Statement at the end of this press release.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts